ÂÜÀòÂÒÂ×

Tiffany Coles is an experienced professional in drug safety and pharmacovigilance, currently serving as Director of Drug Safety and Pharmacovigilance at Halozyme Therapeutics, Inc. since January 2019. Previous roles include Associate Director of Patient Safety and Pharmacovigilance at the Parker Institute for Cancer Immunotherapy and Pharmacovigilance Manager at Anges MG, Inc. Tiffany has a comprehensive background in managing drug safety operational strategies, developing safety management plans, performing compliance monitoring, providing vendor oversight, and collaborating across teams for clinical trial conduct. Tiffany holds a Bachelor of Arts in History from the University of Maryland, earned between 1998 and 2002.